Rapport Therapeutics, Inc.: Jefferies cuts target price to $55 from $64
RAPP•Jefferies cut its target price for Rapport Therapeutics to $55 from $64.
Related News
Industrial firms slide after US midterm results amplify data center demand worries
CAT•
Credit card firms fall as Democrats sweep Congress
XLF•
Newmark arranges $130 million sale of NorthBay Health property portfolio in California
NMRK•
Array Technologies names Shoals' Brandon Moss CEO of combined company upon merger close
ARRY•